CCAT1: A Drug Target / Disease Biomarker (G100507056)

Target Name: CCAT1

NCBI ID: G100507056

CCAT1

Other Name(s): CARLo-5 | colon cancer associated transcript 1 | CARLO5 | onco-lncRNA-40 | Colon cancer associated transcript 1

CCAT1: A Drug Target / Disease Biomarker

CCAT1, also known as cancer cell adhesion molecule 1, is a protein that is expressed in various tissues of the body, including the lungs, breast, and gastrointestinal tract. It is a member of the cadherin family, which is a group of transmembrane proteins that are involved in cell-cell adhesion.

One of the key functions of CCAT1 is its role in cell-cell adhesion. This protein helps to promote the stickiness of cells to one another, allowing them to stick together and form tissues. This is important for many different processes in the body, including the development and maintenance of tissues and organs, and the regulation of cell growth and differentiation.

In addition to its role in cell-cell adhesion, CCAT1 is also involved in many other cellular processes in the body. For example, it has been shown to play a role in the development and progression of various types of cancer, including breast, ovarian, and prostate cancer. It is also involved in the regulation of cell signaling pathways, and has been shown to interact with a wide range of different proteins.

Despite the many important functions of CCAT1, little is known about this protein. There are currently no approved drugs that target CCAT1, and research into this protein is still in its early stages. However, studies have shown that manipulating CCAT1 levels or its activity could be a promising new approach to treating a variety of diseases.

One potential application of CCAT1 as a drug target is in the treatment of breast cancer. Studies have shown that high levels of CCAT1 are associated with poor prognosis in breast cancer patients, and that inhibiting CCAT1 activity may be an effective way to improve treatment outcomes. Additionally, some studies have suggested that CCAT1 may be a potential biomarker for breast cancer, as its levels may be able to be used as a diagnostic indicator of the disease.

Another potential application of CCAT1 as a drug target is in the treatment of other diseases. For example, studies have shown that high levels of CCAT1 are associated with the development of various types of cancer, including colon cancer. Therefore, targeting CCAT1 activity may be a promising approach to treating colon cancer. Additionally, some studies have suggested that CCAT1 may be involved in the regulation of cell signaling pathways, which could make it a potential target for diseases that are characterized by the over-regulation or under-regulation of signaling pathways.

In conclusion, CCAT1 is a protein that is involved in a wide range of cellular processes in the body. While currently there are no approved drugs that target CCAT1, research into this protein is still in its early stages, and manipulating its levels or activity may be a promising new approach to treating a variety of diseases. Further studies are needed to fully understand the role of CCAT1 in the body and its potential as a drug target.

Protein Name: Colon Cancer Associated Transcript 1

The "CCAT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCAT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets